Logo
Nazad
V. Subbiah, V. Sahai, Dejan Maglic, Kamil Bruderek, B. Touré, Songping Zhao, R. Valverde, Patrick J O'Hearn, D. Moustakas, Heike Schonherr, Nastaran Gerami-Moayed, Alexander M Taylor, B. M. Hudson, Damian J Houde, Debjani Pal, Lindsey Foster, H. Gunaydin, P. Ayaz, Dina A Sharon, L. Goyal, A. Schram, Suneel D. Kamath, C. Sherwin, O. Schmidt-Kittler, K. Jen, F. Ricard, B. Wolf, D. Shaw, D. Bergstrom, J. Watters, Jessica B Casaletto
23 4. 6. 2023.

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

Unlike pan-FGFR inhibitors, RLY-4008 was designed to be selective for FGFR2 and induces clinical responses in FGFR2-altered solid tumors without clinically significant FGFR1-mediated hyperphosphatemia and FGFR4-mediated diarrhea.


Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više